LipidSeq: a next-generation clinical resequencing panel for monogenic dyslipidemias[S]

• Main Authors: Christopher T. Johansen, Joseph B. Dubé, Melissa N. Loyzer, Austin MacDonald, David E. Carter, Adam D. McIntyre, Henian Cao, Jian Wang, John F. Robinson, Robert A. Hegele
• Format: Article
• Language: English
• Published: Elsevier 2014-04-01
• Series: Journal of Lipid Research
• Subjects: next generation sequencing; DNA diagnosis; familial dyslipidemia; Sanger sequencing; mutations; genetic risk score
• Online Access: http://www.sciencedirect.com/science/article/pii/S0022227520376653

We report the design of a targeted resequencing panel for monogenic dyslipidemias, LipidSeq, for the purpose of replacing Sanger sequencing in the clinical detection of dyslipidemia-causing variants. We also evaluate the performance of the LipidSeq approach versus Sanger sequencing in 84 patients with a range of phenotypes including extreme blood lipid concentrations as well as additional dyslipidemias and related metabolic disorders. The panel performs well, with high concordance (95.2%) in samples with known mutations based on Sanger sequencing and a high detection rate (57.9%) of mutations likely to be causative for disease in samples not previously sequenced. Clinical implementation of LipidSeq has the potential to aid in the molecular diagnosis of patients with monogenic dyslipidemias with a high degree of speed and accuracy and at lower cost than either Sanger sequencing or whole exome sequencing. Furthermore, LipidSeq will help to provide a more focused picture of monogenic and polygenic contributors that underlie dyslipidemia while excluding the discovery of incidental pathogenic clinically actionable variants in nonmetabolism-related genes, such as oncogenes, that would otherwise be identified by a whole exome approach, thus minimizing potential ethical issues.